fbpx



PROGRAM
October 8-10, 2021

Beijing time
GMT +8

Session 1 (5.30 pm – 6.35 pm)

Real-world data, Covid-19 & biomarkers

  • Heart failure in the real world in 2021 – Lars Lund, Sweden
  • Biomarkers in HF for diagnosis & treatment
    guidance – Update 2021
    James Januzzi, USA
  • Managing HF patients in COVID-19 times
    Pedro Schwartzmann, Brazil
  • New devices to assess lung water & guide HF therapy (CardioMems, Medical Sensible, Vectorious)
  • Big data and AI for heart failure – What is on the horizon?
    Vidur Mahajan, India
  • Panel discussion
Athens time
GMT +3

Session 3 (5.30 pm – 6.35 pm)

State of the art management of chronic HF

  • RAASi/ARNi, MRAs and beta blockers
    Michael Böhm, Germany
  • SGLT2 inhibitors overview 2021
    John McMurray, UK
  • SGLT2 inhibitors: focus on renal outcomes
    Milton Packer, USA
  • Vericiguat, the new drug
    Burkert Pieske, Germany
  • Managing to start the 4 foundational therapies quickly – Why? How?
    Giuseppe Rosano, UK
  • Panel discussion
NY time
GMT -4

Session 5 (5.30 pm – 6.35 pm)

Update on advanced HF, assist devices and heart transplantation

  • What about patients with LVEEF <20%
  • Mechanical circulatory support (MCS)
  • Organising cardiac surgery and interventional care for HF
    Terrence M. Yau, Canada
  • Destination LVAD
    Mandeep Mehra, USA
  • Heart transplantation
  • Panel discussion
Break (6.35 pm – 6.45 pm)
Break (7.30 pm – 7.40 pm)

Session 2 (7.40 pm – 8.0 pm)

The new HF guidelines: diagnostic & treatment algorithms

  • Diagnostic algorithm for heart failure
    Justin Ezekowitz, USA
  • Diagnostic approaches in HFpEF
    Rudolf de Boer, Netherlands
  • HfrEF vs. HfmrEF vs. HfpEF – Similarities and differences
    Yuri Lopatin, Russia
  • Treatment algorithm of HfrEF
    Marco Metra, Italy
  • Treatment approaches in HfpEF
    Kavita Sharma, USA
  • Panel discussion
Break (6.35 pm – 6.45 pm)
Break (7.30 pm – 7.40 pm)

Session 4 (7.40 pm – 8.0 pm)

Acute HF and the transition to ambulatory care

  • Management of AHF – An overview
  • Post MI acute heart failure
    Javed Butler, USA
  • Inflammatory cardiomyopathy and viral myocarditis
    Biykem Bozkurt, USA
  • Cardiogenic shock
    Yuhui Zhang, China
  • Starting new drugs classes in hospital & organizing the discharge process
    Ovidiu Chioncel, Romania
  • Panel discussion
Break (6.35 pm – 6.45 pm)
Break (7.30 pm – 7.40 pm)

Session 6 (7.40 pm – 8.0 pm)

Difficult problems in HF

  • HF patients with a suspicion of amyloid
    Shelley Zieroth, Canada
  • Heart failure in women – What is important to know?
    Karen Sliwa-Hahnle, South Africa
  • The symptomatic patient with every drug treatment on board and no obvious co-morbidity
  • Management of heart failure in low resource settings
    Clara Ines Saldarriaga, Colombia
  • The patient with cancer and cardio-toxic chemotherapy
    Alexander Lyon, UK
  • Panel discussion
Beijing time
GMT +8

Session 7 (5.30 pm – 6.35 pm)

Co-morbidities in HF affecting QoL and hard outcomes (part 1)

  • What can the patients with poor QoL teach us?
    John Spertus, USA
  • Sleep Apnea
    Andrew J. S. Coats, Australia
  • Prevention of Atrial Fibrillation
    John Atherton, Australia
  • Treatment of Atrial Fibrillation
    Paulus Kirchhof, Germany
  • Managing obesity, frailty and cachexia
    Magdy Abdelhamid, Egypt
  • Panel discussion
Athens time
GMT +3

Session 9 (5.30 pm – 6.35 pm)

Valvular heart disease in HF

  • State of art for imaging for diagnosis of valvular disease and assessment of risk
    Fausto Pinto, Portugal
  • Aortic valve disease
  • Tricuspid disease
    William T. Abraham, USA
  • Mitral valve disease – Focus on MitraClip
    Gregg Stone, USA
  • Mitral valve disease – Focus on Carillon
    Horst Sievert, Germany
  • Panel discussion
NY time
GMT -4

Session 2 (5.30 pm – 6.35 pm)

The new HF guidelines: diagnostic & treatment algorithms

  • Diagnostic algorithm for heart failure
    Justin Ezekowitz, USA
  • Diagnostic approaches in HFpEF
    Rudolf de Boer, Netherlands
  • HfrEF vs. HfmrEF vs. HfpEF – Similarities and differences
    Yuri Lopatin, Russia
  • Treatment algorithm of HfrEF
    Marco Metra, Italy
  • Treatment approaches in HfpEF
    Kavita Sharma, USA
  • Panel discussion
Break (6.35 pm – 6.45 pm)
Break (7.30 pm – 7.40 pm)

Session 8 (7.40 pm – 8.0 pm)

Co-morbidities in HF affecting QoL and hard outcomes (part 2)

  • CKD
  • Diabetes in HF
    John Cleland, UK
  • Diabetic Kidney Disease
    Gerasimos Filippatos, Greece
  • Hyperkalemia
    Mikhail Kosiborod, USA
  • ID with and without anaemia
    Stefan Anker, Germany
  • Panel discussion
Break (6.35 pm – 6.45 pm)
Break (7.30 pm – 7.40 pm)

Session 1 (7.40 pm – 8.0 pm)

Real-world data, Covid-19 & biomarkers

  • Heart failure in the real world in 2021 – Lars Lund, Sweden
  • Biomarkers in HF for diagnosis & treatment
    guidance – Update 2021
    James Januzzi, USA
  • Managing HF patients in COVID-19 times
    Pedro Schwartzmann, Brazil
  • New devices to assess lung water & guide HF therapy (CardioMems, Medical Sensible, Vectorious)
  • Big data and AI for heart failure – What is on the horizon?
    Vidur Mahajan, India
  • Panel discussion
Break (6.35 pm – 6.45 pm)
Break (7.30 pm – 7.40 pm)

Session 3 (7.40 pm – 8.0 pm)

State of the art management of chronic HF

  • RAASi/ARNi, MRAs and beta blockers
    Michael Böhm, Germany
  • SGLT2 inhibitors overview 2021
    John McMurray, UK
  • SGLT2 inhibitors: focus on renal outcomes
    Milton Packer, USA
  • Vericiguat, the new drug
    Burkert Pieske, Germany
  • Managing to start the 4 foundational therapies quickly – Why? How?
    Giuseppe Rosano, UK
  • Panel discussion
Beijing time
GMT +8

Session 4 (5.30 pm – 6.35 pm)

Acute HF and the transition to ambulatory care

  • Management of AHF – An overview
  • Post MI acute heart failure
    Javed Butler, USA
  • Inflammatory cardiomyopathy and viral myocarditis
    Biykem Bozkurt, USA
  • Cardiogenic shock
    Yuhui Zhang, China
  • Starting new drugs classes in hospital & organizing the discharge process
    Ovidiu Chioncel, Romania
  • Panel discussion
Athens time
GMT +3

Session 6 (5.30 pm – 6.35 pm)

Difficult problems in HF

  • HF patients with a suspicion of amyloid
    Shelley Zieroth, Canada
  • Heart failure in women – What is important to know?
    Karen Sliwa-Hahnle, South Africa
  • The symptomatic patient with every drug treatment on board and no obvious co-morbidity
  • Management of heart failure in low resource settings
    Clara Ines Saldarriaga, Colombia
  • The patient with cancer and cardio-toxic chemotherapy
    Alexander Lyon, UK
  • Panel discussion
NY time
GMT -4

Session 8 (5.30 pm – 6.35 pm)

Co-morbidities in HF affecting QoL and hard outcomes (part 2)

  • CKD
  • Diabetes in HF
    John Cleland, UK
  • Diabetic Kidney Disease
    Gerasimos Filippatos, Greece
  • Hyperkalemia
    Mikhail Kosiborod, USA
  • ID with and without anaemia
    Stefan Anker, Germany
  • Panel discussion
Break (6.35 pm – 6.45 pm)
Break (7.30 pm – 7.40 pm)

Session 5 (7.40 pm – 8.0 pm)

Update on advanced HF, assist devices and heart transplantation

  • What about patients with LVEEF <20%
  • Mechanical circulatory support (MCS)
  • Organising cardiac surgery and interventional care for HF
    Terrence M. Yau, Canada
  • Destination LVAD
    Mandeep Mehra, USA
  • Heart transplantation
  • Panel discussion
Break (6.35 pm – 6.45 pm)
Break (7.30 pm – 7.40 pm)

Session 7 (7.40 pm – 8.0 pm)

Co-morbidities in HF affecting QoL and hard outcomes (part 1)

  • What can the patients with poor QoL teach us?
    John Spertus, USA
  • Sleep Apnea
    Andrew J. S. Coats, Australia
  • Prevention of Atrial Fibrillation
    John Atherton, Australia
  • Treatment of Atrial Fibrillation
    Paulus Kirchhof, Germany
  • Managing obesity, frailty and cachexia
    Magdy Abdelhamid, Egypt
  • Panel discussion
Break (6.35 pm – 6.45 pm)
Break (7.30 pm – 7.40 pm)

Session 9 (7.40 pm – 8.0 pm)

Valvular heart disease in HF

  • State of art for imaging for diagnosis of valvular disease and assessment of risk
    Fausto Pinto, Portugal
  • Aortic valve disease
  • Tricuspid disease
    William T. Abraham, USA
  • Mitral valve disease – Focus on MitraClip
    Gregg Stone, USA
  • Mitral valve disease – Focus on Carillon
    Horst Sievert, Germany
  • Panel discussion
Looking to register a group of 10 or more? contact: “[email protected]”.

Thank You!